menu search

Replimune presents rp1 data from the ignyte anti-pd1 failed melanoma cohort and rp2 data in uveal melanoma at the 2023 american society of clinical oncology (asco) annual meeting

Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab cont...

June 3, 2023, 6:15 pm

Bristol myers, nektar melanoma doublet therapy trial fails to show clinical benefit

Bristol Myers Squibb Co (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have an update following the first analysis of the Phase 3 PIVOT IO-001 ...

March 14, 2022, 11:25 am

Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...

February 15, 2022, 9:14 am

Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...

February 15, 2022, 9:14 am

Bristol myers, exelixis tout additional opdivo/cabometyx combo data from kidney cancer trial

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of...

February 15, 2022, 9:14 am


Search within

Pages Search Results: